Search Results - "ROBAK, T"

Synthesis and Applications of tert-Butanesulfinamide by Robak, MaryAnn T, Herbage, Melissa A, Ellman, Jonathan A

“…The chemical properties and applications of tert-butanesulinamide and other sulfinamides are examined. The addition of metalloenamies to azocarboxylates is…”
Get full text

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M., Buske, C.

Get full text

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C.U., Kater, A.P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., Hallek, M., Mey, U.

“…•These updated ESMO Clinical Practice Guidelines provide key recommendations on the management of chronic lymphocytic leukaemia (CLL)•Authorship includes a…”
Get full text

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia by Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Jurczak, Wojciech, Kaźmierczak, Maciej, Lamanna, Nicole, O’Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan-Der-Yu, Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen, Shadman, Mazyar

“…In this trial in patients with relapsed CLL, progression-free survival at 2 years was 78% with zanubrutinib and 66% with ibrutinib. Infections were common with…”
Get full text

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E., Hallek, M.

Get full text

Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Robak, T., Matutes, E., Catovsky, D., Zinzani, P.L., Buske, C.

Get full text

Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies by Smolewski, P, Robak, T

“…Apoptosis, a programmed cell death, plays a key role in the regulation of tissue homeostasis. However, impairment of its regulation may promote formation and…”
Get more information

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma by Jurczak, W., Zinzani, P.L., Gaidano, G., Goy, A., Provencio, M., Nagy, Z., Robak, T., Maddocks, K., Buske, C., Ambarkhane, S., Winderlich, M., Dirnberger-Hertweck, M., Korolkiewicz, R., Blum, K.A.

“…This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed…”
Get full text

Enantioselective Addition of Thioacetic Acid to Nitroalkenes via N-Sulfinyl Urea Organocatalysis by Kimmel, Kyle L, Robak, MaryAnn T, Ellman, Jonathan A

“…The highly enantioselective addition of thioacetic acid to nitroalkenes using a new sulfinyl urea organocatalyst is described. The addition of thioacetic acid…”
Get full text

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms by Treliński, J, Robak, T

“…The Janus family kinases (JAKs), JAK1, JAK2, JAK3, and TYK2, are involved in cell growth, survival, development, and differentiation of a variety of cells,…”
Get more information

A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia by Robak, P, Robak, T

“…Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways,…”
Get more information

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) by Chanan-Khan, A, Egyed, M, Robak, T, Martinelli de Oliveira, F A, Echeveste, M A, Dolan, S, Desjardins, P, Blonski, J Z, Mei, J, Golany, N, Zhang, J, Gribben, J G

Get full text

Development of an N-sulfinyl prolinamide for the asymmetric aldol reaction by Robak, MaryAnn T., Herbage, Melissa A., Ellman, Jonathan A.

“…A new class of organocatalysts is reported that incorporates an N-sulfinyl amide in place of the carboxylic acid of proline to serve as a hydrogen bond donor,…”
Get full text

Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity by Robak, E, Robak, T

“…Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell hyperactivity and defective T-cell function, and several cytokine…”
Get more information

Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment‐Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial by Phillips, T., Wang, M., Robak, T., Gallinson, D., Stevens, D., Patel, K., Ramadan, S., Wun, C., Jurczak, W., Smith, S. D.

Get full text

Developing a Green Chemistry Focused General Chemistry Laboratory Curriculum: What Do Students Understand and Value about Green Chemistry? by Armstrong, Laura B, Rivas, Mariana C, Zhou, Zeyi, Irie, Lauren M, Kerstiens, Geri A, Robak, MaryAnn T, Douskey, Michelle C, Baranger, Anne M

“…Over the past several decades, green chemistry has gained prominence in chemistry education. However, the development of green chemistry curricula has not…”
Get full text

Enantio- and diastereoselective addition of thioacetic acid to nitroalkenes via N-sulfinyl urea catalysis by Kimmel, Kyle L., Robak, MaryAnn T., Thomas, Stephen, Lee, Melissa, Ellman, Jonathan A.

“…The enantioselective addition of thioacetic acid to nitroalkenes was achieved using N-sulfinyl urea catalysis. In this report, the scope of the reaction was…”
Get full text

Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database by Brown, J. R., Eichorst, B., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., Ma, H., Tedeschi, A.

Get full text

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies) by Eichhorst, B, Robak, T, Montserrat, E, Ghia, P, Hillmen, P, Hallek, M, Buske, C

Get full text

P868: A CIRCULATING SERUM MIRNAS‐BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB‐BASED REGIMENS by Puła, A., Robak, P., Jarych, D., Mikulski, D., Dróżdż, I., Szemraj, J., Robak, T.

Get full text